gives similar information for the 43 patients who died from causes unassociated with marrow failure. The most striking difference in distribution from Fig 9 is due to the patients who died in the first three years from vascular catastrophes. Dramatic and distressing though the few acute blastic terminations have been, it should be noted that this transformation has never occurred less than two-and-a-half years after the first treatment.
Had we a method of ascertaining which patients were going to undergo acute marrow failure in the course of their illness, there might be a case for withholding irradiation and trying other forms of treatment. But as there is no such method, we feel that in the present state of our knowledge there is no absolute contraindication to 32p in any patient with polycythkmia vera.
Acknowledgments: I am grateful to the staff of the Royal Marsden Hospital, and particularly Dr J B Harman under whose care the great majority of the patients have been, for allowing me to discuss this group. My thanks are also due to Professor D W Smithers for asking me to undertake this work, to Venesection has its place in the relief of symptoms before radioactive phosphorus or chemotherapy can act, a period of three to six weeks. Various drugs have been proposed from time to time for the management of polycythaemia. Before 1940 phenylhydrazine was used; this is a dangerous hwemolytic substance and it was replaced when the nitrogen mustard group came into use.
Originally intravenous nitrogen mustard was used, but this is rather a violent drug and its use is now confined to severe and late cases. Other alkylamines have been tried for the control of polycythmmia as they have been introduced, but few have been successful. Thiotepa, introduced in 1956 by Leonard et al., was useful because it could be given intramuscularly; up to fourteen months' remission was obtained from a single course of treatment. Mannomustine produced remissions up to ten months, but other alkylating agents, including the recently introduced uramustine, have been disappointing; triaziquone, an oral preparation, is at present under trial and so far has given encouraging results.
The two drugs most used at present are busulphan and pyrimethamine. Busulphan was originally introduced by Galton (1953) for the treatment of chronic myeloid leukemia and was first used by Wald et al. (1958) for polycythemia. We have treated some thirty patients with it and obtained reasonable initial results in most patients. Remissions of up to three years without treatment have been recorded, but most patients need further treatment within eighteen months. A small dose, 4 mg daily, is given initially; it is about eight weeks before real changes in the blood levels and the size of the spleen appear, and then the dose is reduced to 2 mg daily or even less; usually a course of treatment lasting about three months is needed to obtain normal levels. Busulphan reduces the raised alkaline phosphatase in the granulocytes and also reduces the platelet count; one of the undesirable effects of busulphan is that sometimes the platelets are selectively affected and treatment has to be stopped because the level is too low. But busulphan produces no other undesirable side-effects and it is very useful as initial treatment for the first few years.
Pyrimethamine was originally introduced in 1954 but first reports were unfavourable. In 1961 Pegg & Ford presented a dosage scheme which was satisfactory and gave encouraging results. In Manchester we have found it useful and have treated some 40 patients. Troublesome side-effects occur more often than with other drugs, but if the patient reacts satisfactorily, good control can be obtained. The usual dose is 25 mg daily at first, reducing to alternate days as soon as the PCV begins to fall. The platelet count must be watched since a symptomless thrombocytopenia can develop; if this happens, halving the dose is usually a sufficient reduction. In a successful case the raised PCV, the leucocytosis and the thrombocytosis are all reduced to normal levels. We take a PCV of 50 % as the level at which -treatment should be stopped. Remissions of up to -fourteen months without further treatment have been obtained. Troublesome side-effects are nausea, vomiting, anorexia, buccal ulceration and even exfoliative dermatitis. If thrombocytopenia progresses rapidly, epistaxis and purpura can occur. Since pyrimethamine is a folic-acid antagonist, unusually rapid action on erythropoiesis can produce a megaloblastic anemia. Fortunately all these more serious side-effects respond quickly to withdrawal of pyrimethamine and administration of folic acid. In practice we find that a majority of patients are satisfactorily controlled by chemotherapy with reasonable remissions between courses of -treatment. A minority, perhaps 25%, are really -troublesome and in some of these chemotherapy is so unsuccessful that it has to be abandoned. Fig 1 shows a ' successful' case, a woman of 40 who responded well to busulphan treatment and had a three-year remission; Fig 2 shows an 'unsuccessful' case, a patient aged 61 who failed to respond to busulphan or pyrimethamine and who was eventually sent for 32P treatment; The response to 32P was quite violent and appears to be of short duration. In a series of 127 patients followed in Manchester (Perkins et al. 1964 ), chemotherapy without radiation at any time was used. The median survival of this group was 13-6 years, which is much the same as the figure of 13-3 years given by Masouredis & Lawrence (1957) for their series of patients treated with radiophosphorus. It is clear that chemotherapy is considerably more troublesome both to patient and doctor than radiophosphorus treatment; patients on chemotherapy must attend regularly for blood counts at frequent intervals in the initial stages so that the dose can be adjusted, and on the whole the interval between courses of treatment is shorter. Why then bother with chemotherapy at all?
In Manchester we began using chemotherapy when we were working on mustard drugs and wished to define their scope. Quite early the question arose of the possible ill-effects of radiation therapy in patients who survived for many years. The best way to settle the question seemed to be for us to maintain as many polycythamic patients as possible on chemotherapy with or without venesection, and since polycythemic patients live a long time on the average, a programme of many years' duration had to be put into effect. In the event we observed a group of patients for a period of over twenty years. Two striking findings of this survey were: (1) Survival of the patients on chemotherapy is just as good as with radiotherapy. (2) Acute leukemia is not a natural complication of the disease, though about 4% develop myelofibrosis which causes a leukxmoid reaction in the blood. The occurrence of acute leukxemia in polycythamic patients treated with radiotherapy has lately been the subject of several publications. A lengthy study of 1,222 patients in the USA has been made by Modan & Lilienfeld (1965) ; acute leukemia occurred in 11 % of their patients treated with radiophosphorus and in 8X9% of those treated by X-rays, and they considered that the increased risk of acute leukaemia was dependent on the dose of radiation received. However, Halnan & Russell (1965) , working at the Manchester radiotherapy centre, found no case of acute leukemia among 107 patients treated with radiotherapy; but other single well-documented cases have appeared in the recent literature. What we have learnt about the possible leukaemogenic effects of therapeutic radiation, taken together with these reported results, at least makes it undesirable to use radiotherapy for the minority of polycytheemic patients who develop the disease under the age of, say, 50 years; for older patients the risk may well be acceptable in view of the long survival before complications appear.
Another group of patients who have to be given chemotherapy are those who do not respond well to radiophosphorus. Estimates of the size of this group vary, but Halnan & Russell (1965) record that out of 95 patients given 32P treatment, 23 needed additional chemotherapy. A third group who will need chemotherapy are those who, for geographical reasons, cannot travel to a centre where radiotherapy is available; such a situation rarely arises in this country, but we are unusually fortunate in this respect.
For all these reasons it is important to work out a satisfactory scheme of chemotherapy for patients with polycythemia vera. The methods outlined here are the best available at the moment, but we are far from satisfied with them, and we hope that better drugs with fewer side-effects will be developed in the future.
